Body Mass Index and Body Surface Area and Their Associations with Outcomes in Stage II and III Colon Cancer
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Our study aims were to measure the associations between body mass index (BMI) and body surface area (BSA) with outcomes for stage II and III colon cancer and to evaluate if the effect of obesity is modified by disease stage and receipt of adjuvant therapy.
Using a prospective cohort of stage II and III colon cancer patients who were referred between 2001 and 2005, we compared 3-year relapse-free survival (3-year RFS), 5-year cancer-specific survival (5-year CSS), and 5-year overall survival (5-year OS) rates among different BMI and BSA categories. Cox proportional-hazards models were constructed to explore the relationships between different body compositions and outcomes while adjusting for confounders.
Postoperative height and weight were used to classify 913 patients as normal weight (n = 424, BMI <25 kg/m2), overweight (n = 319, BMI 25–30 kg/m2), and obese (n = 170, BMI >30 kg/m2). Using Mosteller formula, 684 subjects had normal BSA (≤2.0 m2) and 229 had high BSA (>2.0 m2). Obese subjects experienced similar 3-year RFS (61.9 vs. 66.5 vs. 63.6 %, p = 0.51), 5-year CSS (65.6 vs. 72.4 vs. 68.0 %, p = 0.22), and 5-year OS (60.8 vs. 64.0 vs. 62.2 %, p = 0.69) when compared to overweight subjects and those with normal BMIs, respectively. Likewise, individuals with high BSA had similar outcomes as those with normal BSA (66.2 vs. 63.6 %, p = 0.64 for 3-year RFS, 70.3 vs. 68.6 %, p = 0.62 for 5-year CSS, and 64.5 vs. 61.9 %, p = 0.48 for 5-year OS). In Cox models, advanced age, male gender, stage III disease, and poor performance status correlated with inferior RFS, CSS, and OS, but BMI and BSA did not.
Obesity as measured by either BMI or BSA was not associated with differences in outcomes in stage II and III colon cancer.
- Siegel RL, Jemal A, Thun MJ, Hao Y, Ward EM. Trends in the incidence of colorectal cancer in relation to county-level poverty among blacks and whites. J Natl Med Assoc. 2008;100:1441–4.
- Siegel RL, Jemal A, Ward EM. Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev. 2009;18:1695–8. CrossRef
- Siegel RL, Ward EM, Jemal A. Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992–2008. Cancer Epidemiol Biomarkers Prev. 2012;21:411–6. CrossRef
- Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev. 2007;16:2533–47. CrossRef
- Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78. CrossRef
- Ning Y, Wang L, Giovannucci EL. A quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies. Obes Rev. 2010;11:19–30. CrossRef
- Murphy TK, Calle EE, Rodriguez C, Kahn HS, Thun MJ. Body mass index and colon cancer mortality in a large prospective study. Am J Epidemiol. 2000;152:847–54. CrossRef
- Vincent AM, Feldman EL. Control of cell survival by IGF signaling pathways. Growth Horm IGF Res. 2002;12:193–7. CrossRef
- LeRoith D, Roberts Jr CT. The insulin-like growth factor system and cancer. Cancer Lett. 2003;195:127–37. CrossRef
- Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Nelson H, et al. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol. 2008;26:4109–15. CrossRef
- Dignam JJ, Polite BN, Yothers G, Raich P, Colangelo L, O’Connell MJ, et al. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. J Natl Cancer Inst. 2006;98:1647–54. CrossRef
- Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317:1098.
- Tang PA, Heng DY, Choueiri TK. Impact of body composition on clinical outcomes in metastatic renal cell cancer. Oncologist. 2011;16:1484–6. CrossRef
- Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–55. CrossRef
- Meyerhardt JA, Tepper JE, Niedzwiecki D, Hollis DR, McCollum AD, Brady D, et al. Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. J Clin Oncol. 2004;22:648–57. CrossRef
- Tartter PI, Slater G, Papatestas AE, Aufses Jr AH. Cholesterol, weight, height, Quetelet’s index, and colon cancer recurrence. J Surg Oncol. 1984;27:232–5. CrossRef
- Haydon AM, Macinnis RJ, English DR, Giles GG. Effect of physical activity and body size on survival after diagnosis with colorectal cancer. Gut. 2006;55:62–7. CrossRef
- Hebert JR, Augustine A, Barone J, Kabat GC, Kinne DW, Wynder EL. Weight, height and body mass index in the prognosis of breast cancer: early results of a prospective study. Int J Cancer. 1988;42:315–8. CrossRef
- Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev. 2001;10:345–53.
- Petrelli JM, Calle EE, Rodriguez C, Thun MJ. Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control. 2002;13:325–32. CrossRef
- Rodriguez C, Calle EE, Fakhrabadi-Shokoohi D, Jacobs EJ, Thun MJ. Body mass index, height, and the risk of ovarian cancer mortality in a prospective cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2002;11:822–8.
- Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocrinol Relat Cancer. 2007;14:189–206. CrossRef
- Stoll BA. Oestrogen/insulin-like growth factor-I receptor interaction in early breast cancer: clinical implications. Ann Oncol. 2002;13:191–6. CrossRef
- Kroenke CH, Chen WY, Rosner B, Holmes MD. Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol. 2005;23:1370–8. CrossRef
- Cleveland RJ, Eng SM, Abrahamson PE, Britton JA, Teitelbaum SL, Neugut AI, et al. Weight gain prior to diagnosis and survival from breast cancer. Cancer Epidemiol Biomarkers Prev. 2007;16:1803–11. CrossRef
- Body Mass Index and Body Surface Area and Their Associations with Outcomes in Stage II and III Colon Cancer
Journal of Gastrointestinal Cancer
Volume 44, Issue 2 , pp 203-210
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Body mass index
- Body surface area
- Colon cancer
- Industry Sectors
- Author Affiliations
- 1. Department of Medicine, University of British Columbia, 2775 Laurel Street, Vancouver, BC, Canada, V5Z 1M9
- 2. Division of Medical Oncology, British Columbia Cancer Agency, Vancouver Clinic, 4415-600 West 10th Avenue, Vancouver, BC, Canada, V5Z 4E6
- 3. Cancer Surveillance and Outcomes, British Columbia Cancer Agency, 686 West Broadway, 8th Floor, Vancouver, BC, Canada, V5Z 1G1